Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Thankyou, Beartrap.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
longfellow95 Member Profile
 
Followed By 23
Posts 4,384
Boards Moderated 0
Alias Born 04/05/15
160x600 placeholder
CLS Holdings (CLSH) Record Sales Just Reported - Most Undervalued Cannabis Stocks InvestorsHub NewsWire - 9/10/2019 7:00:09 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:22:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2019 5:05:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/18/2019 6:02:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 5:24:27 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/28/2019 12:11:21 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/2/2019 5:23:33 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/19/2019 5:19:39 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:33:33 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:20:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/7/2019 5:26:54 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/8/2019 6:04:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2018 4:18:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:17:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/28/2018 5:28:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 1:44:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2018 5:38:07 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/15/2018 3:15:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 4:49:26 PM
longfellow95   Thursday, 09/12/19 02:03:45 AM
Re: beartrap12 post# 243792
Post # of 244451 
Thankyou, Beartrap.
It's good to have that bit of extra confirmation that DCVax-L is being used to treat a few patients in the UK.

It is the UK Specials programme that allows this to happen.
It has to be at the request of a physician directly responsible for the individual patient concerned. And to meet the special needs of that individual patient that cannot be met with a licensed product.
The supplier cannot 'solicit' orders.
The supplier is able to set a price and be reimbursed.
The manufacturer has to have a UK Specials Licence.
And our manufacturer is Advent, operating out of CCGTT (who have the appropriate licence) in London, where Mark Lowdell is the Director.

One assumes that numbers are very small. Maybe 1 or 2 a month, though that's just a guess.

Clearly, it will be UK neuro-oncologists/surgeons with an awareness of DCVax-L, who will be doing the prescribing.
And most likely Dr Ashkan does some of these. But not necessarily all of them.
Suspected or actual adverse events must be reported.

I don't think the patient has to be a UK citizen necessarily.
And the UK Special drug can be exported for use on a patient in a different EU state.

What is not entirely clear to me is who pays.
I think it is down to the patient (hence the online funding appeals), but the guidance document doesn't actually say that the NHS doesn't do the funding.

So NWBO can certainly cover all their costs in relation to supply under UK Specials, and there is nothing to preclude a profit element.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf




Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist